Tvardi Therapeutics
TVRD
56 hedge funds and large institutions have $44.9M invested in Tvardi Therapeutics in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 3 closing their positions.
1,298% more capital invested
Capital invested by funds: $3.21M → $44.9M (+$41.7M)
767% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 3
88% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 8
70% more funds holding
Funds holding: 33 → 56 (+23)
16.16% more ownership
Funds ownership: 4.62% → 20.78% (+16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Slate Path Capital
New York
|
+$16.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.1M |
| 3 |
BlackRock
New York
|
+$5.85M |
| 4 |
6CM
683 Capital Management
New York
|
+$4.16M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$249K |
| 2 |
Millennium Management
New York
|
-$88.3K |
| 3 |
LPL Financial
San Diego,
California
|
-$61.6K |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$71 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$71 |
TVRD Hedge Fund Activity: Q2 2025 in Review
56 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q2 2025, worth a combined $44.9M — up 1,298% from $3.21M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new TVRD positions and 3 closed out — a net gain of 23 holders — while 15 added to existing stakes and 8 trimmed.
The largest buyer was Slate Path Capital, opening a new position worth an estimated $16.6M. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $249K sold.
- 56 institutional investors held Tvardi Therapeutics (TVRD) as of Q2 2025, up from 33 in Q1 2025.
- Funds reported $44.9M of Tvardi Therapeutics stock for Q2 2025, up 1,298% quarter-over-quarter.
- 26 funds opened new Tvardi Therapeutics positions in Q2 2025 and 3 closed out, a net change of +23 holders.
- The largest Tvardi Therapeutics buyer in Q2 2025 was Slate Path Capital, an estimated $16.6M added.
- The largest Tvardi Therapeutics seller in Q2 2025 was Two Sigma Advisers, an estimated $249K sold.
Based on aggregated 13F filings for Q2 2025.